Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in adults 65 years of age and older: A phase II, observer-blind, randomized, controlled trial

Vaccine

Volumn 35, Issue 15, 2017, Pages 1865-1872

  Madan, Anuradha ^a   Ferguson, Murdo ^b   Rheault, Paul ^c   Seiden, David ^d   Toma, Azhar ^e   Friel, Damien ^f   Soni, Jyoti ^g   Li, Ping ^a   Innis, Bruce L ^a   Schuind, Anne ^a  

^a GLAXOSMITHKLINE   (United States)

^b Department of Family Medicine and Emergency Medicine   (Canada)

^c Medicor Research Inc   (Canada)

^d Broward Research Group   (United States)

^e Manna Research   (Canada)

^f GSK   (Belgium)

^g GlaxoSmithKline Pharmaceuticals Ltd   (India)

Author keywords

AS03 adjuvant; Elderly population; H7 influenza vaccine; H7N1; H7N9; Pandemic flu

Indexed keywords

AS 03; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; PLACEBO; UNCLASSIFIED DRUG; VIRUS ANTIBODY; ALPHA TOCOPHEROL; ASO3B ADJUVANT; NEUTRALIZING ANTIBODY; POLYSORBATE; SQUALENE;

AGED; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; DRUG SAFETY; FACIAL NERVE PARALYSIS; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; HUMORAL IMMUNITY; INFLUENZA A; INFLUENZA A VIRUS (H7N1); INFLUENZA A VIRUS (H7N9); INFLUENZA VACCINATION; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADICULITIS; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SERODIAGNOSIS; SHIVERING; SIDE EFFECT; SINGLE BLIND PROCEDURE; SWEATING; VACCINE IMMUNOGENICITY; VERY ELDERLY; VIRUS STRAIN; ADULT; ADVERSE DRUG REACTION; ANIMAL; BLOOD; CLINICAL TRIAL; DRUG COMBINATION; IMMUNOLOGY; NORMAL HUMAN; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-TOCOPHEROL; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DRUG COMBINATIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEALTHY VOLUNTEERS; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H7N1 SUBTYPE; INFLUENZA VACCINES; MALE; NEUTRALIZATION TESTS; PLACEBOS; POLYSORBATES; SINGLE-BLIND METHOD; SQUALENE; VACCINES, INACTIVATED;

EID: 85014819338     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2017.02.057     Document Type: Article

References (17)

1. [1] Gao, R., Cao, B., Hu, Y., Feng, Z., Wang, D., Hu, W., et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 368 (2013), 1888–1897.
2. [2] Wu, P., Peng, Z., Fang, V.J., Feng, L., Tsang, T.K., Jiang, H., et al. Human Infection with Influenza A(H7N9) Virus during 3 Major Epidemic Waves, China, 2013–2015. Emerg Infect Dis 22 (2016), 964–972.
3. [3] Cowling, B.J., Freeman, G., Wong, J.Y., Wu, P., Liao, Q., Lau, E.H., et al. Preliminary inferences on the age-specific seriousness of human disease caused by avian influenza A(H7N9) infections in China, March to April 2013. Euro Surveill, 18, 2013, 20475.
4. [4] Dudley, J.P., Mackay, I.M., Age-specific and sex-specific morbidity and mortality from avian influenza A(H7N9). J Clin Virol 58 (2013), 568–570.
5. [5] Yu, H., Cowling, B.J., Feng, L., Lau, E.H., Liao, Q., Tsang, T.K., et al. Human infection with avian influenza A H7N9 virus: an assessment of clinical severity. Lancet 382 (2013), 138–145.
6. [6] Reber, A.J., Chirkova, T., Kim, J.H., Cao, W., Biber, R., Shay, D.K., et al. Immunosenescence and challenges of vaccination against influenza in the aging population. Aging Dis 3 (2012), 68–90.
7. [7] Jackson, L.A., Campbell, J.D., Frey, S.E., Edwards, K.M., Keitel, W.A., Kotloff, K.L., et al. Effect of varying doses of a monovalent H7N9 influenza vaccine with and without AS03 and MF59 adjuvants on immune response: a randomized clinical trial. JAMA 314 (2015), 237–246.
8. [8] Madan, A., Ferguson, M., Sheldon, E., Segall, N., Chu, L., Toma, A., et al. Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in healthy adults: a phase I/II, observer blind, randomized, controlled trial. Vaccine 35 (2017), 1431–1439.
9. [9] Langley, J.M., Risi, G., Caldwell, M., Gilderman, L., Berwald, B., Fogarty, C., et al. Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study. J Infect Dis 203 (2011), 1729–1738.
10. [10] Langley, J.M., Frenette, L., Ferguson, L., Riff, D., Sheldon, E., Risi, G., et al. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults. J Infect Dis 201 (2010), 1644–1653.
11. [11] Madan, A., Segall, N., Ferguson, M., Frenette, L., Kroll, R., Friel, D., et al. Immunogenicity and safety of an AS03-adjuvanted H7N9 pandemic influenza vaccine in a randomized trial in healthy adults. J Infect Dis, 2016.
12. [12] Heijmans, S., De Meulemeester, M., Reynders, P., Giet, D., Demanet, E., Devresse, P.Y., et al. Immunogenicity profile of a 3.75-μg hemagglutinin pandemic rH5N1 split virion AS03A-adjuvanted vaccine in elderly persons: a randomized trial. J Infect Dis 203 (2011), 1054–1062.
13. [13] Gillard, P., Chu, D.W., Hwang, S.J., Yang, P.C., Thongcharoen, P., Lim, F.S., et al. Long-term booster schedules with AS03A-adjuvanted heterologous H5N1 vaccines induces rapid and broad immune responses in Asian adults. BMC Infect Dis, 14, 2014, 142.
14. [14] Mallett, C.P., Beaulieu, E., Joly, M.H., Baras, B., Lu, X., Liu, F., et al. AS03-adjuvanted H7N1 detergent-split virion vaccine is highly immunogenic in unprimed mice and induces cross-reactive antibodies to emerged H7N9 and additional H7 subtypes. Vaccine 33 (2015), 3784–3787.
15. [15] McElhaney, J.E., Ewen, C., Zhou, X., Kane, K.P., Xie, D., Hager, W.D., et al. Granzyme B: Correlates with protection and enhanced CTL response to influenza vaccination in older adults. Vaccine 27 (2009), 2418–2425.
16. [16] McElhaney, J.E., Dutz, J.P., Better influenza vaccines for older people: what will it take?. J Infect Dis 198 (2008), 632–634.
17. [17] McElhaney, J.E., Xie, D., Hager, W.D., Barry, M.B., Wang, Y., Kleppinger, A., et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol 176 (2006), 6333–6339.